Copyright
©2010 Baishideng.
World J Gastroenterol. Apr 21, 2010; 16(15): 1908-1915
Published online Apr 21, 2010. doi: 10.3748/wjg.v16.i15.1908
Published online Apr 21, 2010. doi: 10.3748/wjg.v16.i15.1908
Study | Disease severity | Probiotic | Control group | Dose of pro-biotic/day) | Treatment duration | N (probiotic/control group) | induction or maintenance of remission N (probiotic/control group) |
Miele et al[13], 2009 | Mild-to-moderate | VSL#3 | Placebo | 450-1800 × 109 | 12 mo | 14/15 | Induction of remission 13/4; Maintenance of remission 11/4 |
Sood et al[12], 2009 | Mild-to-moderate | VSL#3 | Placebo | 3.6 × 1012 | 12 wk | 77/70 | Induction of remission 33/11 |
Henker et al[15], 2008 | Inactive UC | E. coli Nissle 1917 | 5-ASA | 5 × 1010 | 12 mo | 24/10 | Maintenance of remission 18/7 |
Zocco et al[20], 2006 | Inactive UC | Lactobacillus GG | Mesalazine | 18 × 109 | 12 mo | 65/60/62 | Maintenance of remission 55/48/52 |
Matthes et al[11], 2006 | Mild-to-moderate | E. coli Nissle 1917 | Placebo | 10-40 × 108 | 4 wk | 46/11 | Induction of remission 20/2 |
Furrie et al[9], 2005 | Active | Synbiotic (Bifidobacterium longum + inulin-oligofructose) | Potato starch and sachet of 6 g powdered maltodextrose | 4 × 1011 | 4 wk | 9/9 | Induction of remission 5/3 |
Tursi et al[8], 2004 | Mild-to-moderate | Balsalazide/VSL#3 | Mesalazine/balsalazide | 900 × 108 | 8 wk | 30/30/30 | Induction of remission 24/21/16 |
Kruis et al[18], 2004 | Inactive | E. coli Nissle 1917 | Mesalazine | 2.5-25 × 109 | 12 mo | 162/165 | Maintenance of remission 89/104 |
Kato et al[10], 2004 | Mild-to-moderate | Bifidobacterium breve strain Yakult Bifidobacterium bifidum strain Yakult Lactobacillus acidophilus | BFM without B. bifidum and L. acidophilus | 109 | 12 wk | 10/10 | Induction of remission 4/3 |
Cui et al[16], 2004 | Active | Bifidobacteria | Starch | 1.26 g/d | 8 wk | 15/15 | Maintenance of remission 12/1 |
Ishikawa et al[17], 2003 | Mild-to-moderate | Bifidobacterium Breve Bifidobacterium Bifidum Lactobacillus acidophilus YIT 0168 | BFM without these Bifidobacteria | 10 × 108 | 12 mo | 11/10 | Maintenance of remission 8/1 |
Rembacken et al[14], 1999 | Active | E. coli Nissle 1917 serotype O6: K5: H1 | Mesalazine | 5 × 1010 | 12 mo | 57/59 | Induction of remission 39/44; Maintenance of remission 31/27 |
Kruis et al[19], 1997 | Inactive UC | E. coli Nissle 1917 serotype O6: K5: H1 | Mesalazine | 50 × 109 | 12 wk | 50/53 | Maintenance of remission 42/51 |
- Citation: Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. Remission induction and maintenance effect of probiotics on ulcerative colitis: A meta-analysis. World J Gastroenterol 2010; 16(15): 1908-1915
- URL: https://www.wjgnet.com/1007-9327/full/v16/i15/1908.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i15.1908